| 摘要: |
| 目的:探讨大黄䗪虫丸加减联合TP+奥拉帕利对晚期卵巢癌气滞血瘀证患者淋巴细胞的影响。方法:将94例晚期卵巢癌气滞血瘀证患者随机分为治疗组与对照组,每组各47 例。对照组采用TP（紫杉醇+顺铂）联合奥拉帕利治疗,治疗组在对照组基础上加用大黄䗪虫丸治疗。治疗6个月后观察2组的免疫功能;淋巴细胞CD3+、CD4+、CD8+、CD4+/CD8+］水平,血清肿瘤标志物;糖类抗原125（CA125）、糖类抗原199（CA199）、B7同源体4（B7-H4）、人附睾蛋白4（HE4）］水平,生活质量评分（躯体功能、情绪功能、角色功能、认知功能、社会功能、总体健康）及不良反应发生情况。结果:总有效率治疗组为72.34%（34/47）,高于对照组的48.94%（23/47）,差异有统计学意义（P<0.05）。2组各项淋巴细胞水平、血清肿瘤标志物水平、生活质量评分治疗前后组内比较及治疗后组间比较,差异均有统计学意义（P<0.05或P<0.01）。不良反应发生率治疗组为23.40%（11/47）,低于对照组的42.55%（20/47）,差异有统计学意义（P＜0.05）。结论:大黄䗪虫丸加减联合TP+奥拉帕利能改善晚期卵巢癌气滞血瘀证患者的淋巴细胞和血清肿瘤标志物水平,提高生活质量,疗效显著,且安全性高。 |
| 关键词: 卵巢癌 晚期 气滞血瘀证 中西医结合疗法 大黄䗪虫丸 淋巴细胞 |
| DOI： |
|
|
| Effect of modified Dahuang Zhechong pills combined with paclitaxel+cisplatin and Olaparib on lymphocytes in patients with advanced ovarian cancer |
| CHEN Li,ZHAO Wei |
| (The Third Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450006,Henan,China) |
| Abstract: |
| Objective：To investigate the effect of modified Dahuang Zhechong pills combined with paclitaxel+cisplatin and Olaparib on lymphocytes in patients with advanced ovarian cancer with syndrome of Qi stagnation and blood stasis.Methods：A total of 94 patients with advanced ovarian cancer with syndrome of Qi stagnation and blood stasis were randomly divided into treatment group and control group,with 47 patients in each group.The patients in the control group were given paclitaxel+cisplatin combined with Olaparib,and those in the treatment group were given Dahuang Zhechong pills in addition to the treatment in the control group.After 6 months of treatment,the two groups were observed in terms of immune function (the levels of CD3+,CD4+,and CD8+ lymphocytes and CD4+/CD8+ ratio),serum tumor markers ;carbohydrate antigen 125 (CA125),carbohydrate antigen 199 (CA199),B7-H4,and human epididymis protein-4 (HE4)］,quality of life scores (physical function,emotional function,role function,cognitive function,social function,and overall health),and adverse reactions.Results：The treatment group had a significantly higher overall response rate than the control group ;72.34% (34/47) vs 48.94% (23/47),P<0.05］.After treatment,both groups had significant changes in the levels of lymphocytes,the levels of serum tumor markers,and quality of life score,and there were significant differences in these indices between the two groups after treatment (P<0.05 or P<0.01).The treatment group had a significantly lower incidence rate of adverse reactions than the control group ;23.40% (11/47) vs 42.55% (20/47),P<0.05］.Conclusion：In patients with advanced ovarian cancer with syndrome of Qi stagnation and blood stasis,modified Dahuang Zhechong pills combined with paclitaxel+cisplatin and Olaparib can improve the levels of lymphocytes and serum tumor markers and quality of life,with a marked clinical effect and a favorable safety profile. |
| Key words: ovarian cancer advanced syndrome of Qi stagnation and blood stasis integrated traditional Chinese and Western medicine therapy Dahuang Zhechong pills lymphocytes |
